Use of cyclosporine in renal transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S167-S172

  Kyriakides, G ^a   Miller, J ^b  

^a Paraskevaidion Surgical and Transplant Center Nicosia   (Cyprus)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

BIOAVAILABILITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ABSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROEMULSION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 1642344558     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.112     Document Type: Article

References (75)

1. Borel J.F., Feurer C., Gubler H.U., et al. Biological effects of cyclosporine A a new antilymphocytic agent. Agents Actions. 6:1976;468.
2. Baumann G. Molecular mechanism of immunosuppressive agents. Transplant Proc. 24:(suppl 2):1992;4.
3. Calne R.Y., White D.J.G., Thiru S., et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet. ii:1978;1323.
4. Calne R.Y., Rolles K., White D.J.G., et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet. ii:1979;1033.
5. Calne R.Y., White D.J.G., Evans D.B., et al. Cyclosporin A in cadaveric organ transplantation. Br Med J. 282:1981;934.
6. Starzl T.E., Klintmalm G.B.G., Weil R. III, et al. Cyclosporine A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet. 153:1981;486.
7. European Multicentre Trial Group. Cyclosporine A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet. ii:1982;57.
8. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicenter trial. Lancet. ii:1983;986.
9. Calne R.Y., Wood A.J. Cyclosporine in cadaveric renal transplantatation 3 year follow-up of European Multicenter trial. Lancet. ii:1985;549.
10. Calne R.Y. Cyclosporine in cadaveric renal transplantation 5-year follow-up of a multicenter trial. Lancet. ii:1987;506.
11. Canadian Multicentre Trasplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 309:1983;809.
12. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 314:1986;1219.
13. Kahan B.D., Van Buren C.T., Flechner S.M., et al. Cinical and experimental studies with cyclosporine in renal transplantation. Surgery. 97:1985;125.
14. Najarian J.S., Fryd D.S., Strand M., et al. A single institution, randomized, prospective trial of cyclosporine versus azathioprine antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg. 201:1985;142.
15. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 311:1984;699.
16. Fisher N.C., Nightingale P.G., Gunson B.K., et al. Chronic renal failure following liver transplantation a retrospective analysis. Transplantation. 66:1998;59.
17. Bennett W.M., DeMattos A., Meyer M.M., et al. Chronic cyclosporine nephropathy the Achilles' heel of immunosuppressive therapy. Kidney Int. 50:1996;1089.
18. English J., Evans A., Houghton D.C., et al. Cyclosporine induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 44:1987;135.
19. Mason J. Pharmacology of cyclosporine (Sandimmune) VII. Pathology and toxicology of cyclosporine in humans and animals. Pharmacol Rev. 42:1989;423.
20. 1 underlies development of progressive kidney fibrosis. Kidney Int. 45:1994;916.
21. 1 in RNA a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int. 49:1996;1297.
22. Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62:2002;311.
23. Kahan B.D., Wideman C.A., Reid M., et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc. 16:1984;1195.
24. Lindholm A., Kahan B.D. The use of cyclosporine in organ transplantation. Bach J.F. T-cell-directed immunointervention. 1993;77 Blackwell Scientific, London.
25. Thomson A.W., Starzl T.E. Immunosuppressive drugs, developments in anti-rejection therapy. 1994;Edward Arnold, London. p 37.
26. Mueller E.A., Kovarik J.M., Van Bree J.B., et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparizon with the market formulation. Pharm Res. 11:1994;151.
27. Trull A.K., Tan K.K.C., Tan L., et al. Absorption of cyclosporin from conventional and new microemulsion oral formulation in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol. 39:1995;627.
28. Winkler M., Ringe B., Oldhafer K., et al. Influence of bile on cyclosporine absorption from microemulsion formulation in primary liver transplants. Transpl Int. 8:1995;324.
29. Kahan B.D., Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 46:1988;631.
30. Kahan B.D., Dunn J., Fitts C., et al. The Neoral formulation improved correlation between cyclosporine trough levels and exposure in stable renal transplant patients. Kahan B.D. Cyclosporine, the ten-year experience. 1994;2940 Appleton & Lange, Norwalk, Conn.
31. Kovarick J.M., Mueller E.A., Van Bree J.B., et al. Cyclosporin pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation. 58:1994;658.
32. Kovarick J.M., Mueller E.A., Van Bree J.B., et al. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant recipients. Ther Drug Monit. 16:1994;232.
33. Kovarik J.M., Mueller E.A., Van Bree J.B., et al. Reduced inter-and intraindividual variability in cyclosporine pharmacokinetics from. J Pharm Sci. 83:1994;444.
34. Mueller E.A., Kallay Z., Kovarik J.M., et al. Assessment of glomerular filtration rate after multiple administration of a new oral formulation of cyclosporine in clinically stable renal transplant patients. Transplant Proc. 27:1995;834.
35. Keown P., Landsberg D., Halloran P., et al. A randomized prospective nulticenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients report of the Canadian Neoral Renal Transplantations Study Group. Transplantation. 62:1996;1744.
36. Frei U.A., Neumayer H.H., Buchholz B., et al. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. Transplantation. 65:1998;1455.
37. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205.
38. Senel M.F., Van Buren C., Welsh M., et al. Impact of early cyclosporin average blood concentration on early kidney transplant failure. Transplant Int. 11:1998;46.
39. Mahalati K., Belitsky P., West K., et al. Approaching the therapeutic window for cyclosporine in kidney transplantation a prospective study. J Am Soc Nephrol. 12:2001;828.
40. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 68:1999;55.
41. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243.
42. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation. 72:2001;1024.
43. International Neoral Renal Study Group. Randomized international study of cyclosporine microemusion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2:2002;157.
44. 2 monitorng of cyclosporine microemulsion. Transplantation. 76:2003;903.
45. 2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. Transplantation. 75:2003;2086.
46. Kahan B.D., Welsh M., Shoenberg L., et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 62:1996;599.
47. Halloran P., Helms L.M., Kung L., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 68:1999;1356.
48. Lodge J.P., Pollard S.G. Neoral vs Sandimmune. Interim results of a randomized trial of efficacy and safety in new renal transplant recipients. Transplant Proc. 30:1998;1742.
49. Shah M.B., Martin J.E., Schroeder T.J., et al. Evaluation of the safety and tolerability of Neoral and Sandimmune a meta-analysis. Transplant Proc. 30:1998;1697.
50. 2 monitoring a review. Transplantation. 73:(suppl):2002;S3.
51. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321.
52. Sollinger H.W., the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225.
53. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029.
54. Halloran P., Mathew T., Tomlanovich S., et al. or the International Mycophenolate Mofetil Renal Transplant Study Groups Mycophenolate mofetil in renal allograft recipients. Transplantation. 63:1997;39.
55. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation. 68:1999;391.
56. Nashan B., Moore R., Amlot P., et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193.
57. Kahan B.D., Rajugopalan P.R., Hall M., for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric-2-receptor monoclonal antibody. Transplantation. 67:1999;276.
58. Vincenti F., Kirkman R., Light S., et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 338:1998;161.
59. Kahan B.D., Podbielski J., Napoli K.L., et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 66:1998;1040.
60. Kahan B.D., for the Rapamune U.S. Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection a randomized multicentre study. The Rapamune U.S. Study Group. Lancet. 356:2000;194.
61. Oberbauer R., Kreis H., Johnson R.W.G., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen. Transplantation. 76:2003;364.
62. Kreis H., Cisterne J.-M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 69:2000;1252.
63. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 74:2002;1070.
64. Kootte A.M., Lensen L.M., Van Bockel J.H., et al. High- and low-dose regimens of cyclosporine in renal transplantation: immunosuppressive efficacy and side effects. Nephrol Dial Transplant. 3:1988;666.
65. Citterio F., Torricelli P., Serino F., et al. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Transplant Proc. 30:1998;1688.
66. Saunders R.N., Bicknell G.R., Nicholson M.L. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular and histological markers of chronic allograft nephropathy. Transplantation. 75:2003;772.
67. Pascual M., Curtis J., Delmonico F.L., et al. A prospective randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation. 75:2003;1501.
68. Kasiske B.L., Chakkera H.A., Louis T.A., et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 11:2000;1910.
69. Thervet E., Morelon E., Ducloux D., et al. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophnolate mofetil conversion. Clin Transplant. 14:2000;561.
70. Tran H.T.B., Acharya M.K., McKay D.B., et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil and steroids. J Am Soc Nephrol. 11:2000;1903.
71. Mayer A.D., Dmitrewski J., Squifflet J.P., et al. for the European Tacrolimus Multicenter Renal Study Group. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation. 64:1997;436.
72. Pirsch J.D., Miller J., Deierhoi M.H., et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppresion after cadaveric renal transplantation. Transplantation. 63:1997;977.
73. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 69:2000;834.
74. Margreiter R., for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation a randomized multicentre study. Lancet. 359:2002;741.
75. Gonwa T., Johnson C., Ahsan N., et al. Randomized trial of tacrolimus+mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 75:2003;2048.